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INTRODUCTION
Decreased ovarian function during menopause is associated with the widely described increase in cardiovascular diseases occurring in this period of a woman's life (1) . The cardiovascular risk is in part attributable to the altered lipid and glycemic metabolism as well as to the development of the chronic vascular dysfunction (2, 3) . Postmenopausal hormone therapy (HT) exerts some beneficial effects on the glycemic and lipid metabolism but many postmenopausal women either cannot or will not comply with a HT regimen (4, 5) .
In this regard phytoestrogens (PHs), a wide family of plant derived compounds, have become an alternative treatment. In fact the growing body of literature indicates that PH may exert both estrogenic and antiestrogenic effects on the metabolism, depending on their concentration and molecular characteristics (6) . Genistein is one of the most studied PHs, arousing great interest at present. The relative potencies of the different PHs compared with E2 have been assessed using human cell culture bioassays and the relative potency of genistein in comparison with E2 is well established (7) .
Some clinical trials have shown that soy supplementation is associated with a reduction in lipids and lipoproteins in hyper and non-hypercholesterolemic subjects (8) with an improvement in lipid peroxidation biomarkers (9) as well as in vascular reactivity (10) . However, other recent works show soy supplementation to have little effect on the lipid and glycemic metabolism (11) . Thus, despite these conflicting findings, the effects of genistein on vascular reactivity seem to be relevant (12) while the relationship of this PH to the glycemic metabolism might be examined.
Many studies suggest that soy has beneficial effects on diabetes mellitus and obesity. In fact, the supplementation of soy protein supplements seems to determine a reduced insulin response to the oral glucose test challenge in hyperlipidemic subjects (13) , while soy consumption increases the SHBG levels (14) and is inversely associated with impaired glucose tolerance. Jayagopal et al. reported that PH supplementation significantly lowers the mean values for fasting insulin and insulin resistance in postmenopausal type 2 diabetic patients (15) . Recently therefore, more it has been demonstrated that genistein supplementation improves insulin and glucose metabolism in healthy postmenopausal subjects (16) .
In order to analyse thoroughly how genistein administration affects cardiovascular risk markers we investigated the metabolism of glucose and lipids as well as vascular reactivity in postmenopausal subjects with differing metabolic status.
MATERIALS AND METHODS
Fifty postmenopausal women ( aged 53.91 ± 3.94 yr) who had attended the Gynecologic Department of our University for the treatment of menopausal symptoms, were consecutively enrolled in the study protocol. No subjects had taken drugs which might have affected the lipid or glucose metabolism for at least three months before the enrolment or had had diseases known to affect the lipoprotein and the glucose metabolism.
They were 3.9 ± 0.8 yr postmenopausal. Before the beginning of the study an assessment of the plasma follicular stimulating hormone (FSH) and 17-β estradiol (E 2 ) concentration, a mammography, a cervical cytology and a transvaginal ultrasound examination of the ovaries as well as of the endometrial thickness were performed. These parameters were found to be normal and compatible with the menopausal status.
Diabetes, breast cancer, liver or kidney parameter alterations, history of major thromboembolism, thyroid diseases, and uncontrolled or treated hypertension (systolic blood pressure >160 mmHg or diastolic >90 mm Hg) represented exclusion criteria.
Informed consent was obtained from each patient, and the study protocol was approved by our Institutional Review Board.
The body mass index (BMI) was evaluated according to the ratio of weight (kilograms) to height (square meters). To determine of the waist to hip ratio (WHR), the waist circumference was used as the minimum value between the iliac crest and the lateral costal margin, whereas the hip circumference was determined as the maximum value over the buttocks.
The randomization of the subjects was carried out by computer set-up system. The ratio of 2/3 was chosen in order to have as few subjects as possible experiencing menopausal symptoms while excluded 6 from therapy for the 6 months study duration. Patients were therefore assigned to one of two treatment groups: group A (thirty subjects) underwent a therapy with the oral dose of 54 mg/day (three tablets/day) of genistein, while group B (twenty subjects) was treated with a placebo. The active drug and the placebo were similar in appearance and both were administered for at least 24 weeks.
At baseline patients underwent initial hospitalization. Following a standard carbohydrate diet (300 g/d) for 3 days and an overnight fast for 10-12 h, all patients had blood samples for the hormone assessment (testosterone, dehydroepiandrosterone sulfate, androstenedione, 17-hydroxyprogesterone, progesterone, FSH, LH, SHBG , E 2 ) the serum lipid assay [triglycerides, total cholesterol, high and low density lipoproteins (HDL and LDL), very low density lipoprotein (VLDL)], the complete blood count and hepatic and renal markers. On the following day, the patients had an oral glucose tolerance test (OGTT) while the day after the insulin sensitivity was tested with an euglycemic-hyperinsulinemic clamp.
Oral glucose tolerance test data were analyzed as AUC after glucose ingestion, calculated by the trapezoidal rule, and expressed as µIU/mL × 240 minutes for insulin, as ng/mL × 240 minutes for Cpeptide, and as mg/dL × 240 minutes for glucose. The fractional hepatic insulin extraction (FHIE) was calculated by the difference between the incremental AUC-C-peptide (AUC-Cpep) and AUC-insulin (AUC-I) divided by the incremental AUC-Cpep. A normal glycemic response to OGTT was defined according to the criteria of the American Diabetes Association (17) .
According to AUC-I values patients were classified as normoinsulinemic and hyperinsulinemic patients, assuming an AUC-I cut-off value of 10,000 µIU/mL × 240 minutes chosen from arbitrary initial cut-off values examined by using ROC graphs and tested for sensibility and specificity. These values were obtained from about 100 OGTTs that were performed in our postmenopausal population and the 10,000 µIU/mL × 240 minutes threshold showed an optimal predictive performance compared with several other indexes of insulin resistance (18) .
The hyperinsulinemic-euglycemic clamp was performed after a 10-hour overnight fast to estimate peripheral insulin sensitivity. At 8:00 am, an IV catheter was placed in the antecubital vein for the infusion of glucose and insulin. Another catheter was placed in the dorsal vein of the contralateral hand 7 for blood withdrawal which was warmed to 65°C with a warming box. A primed constant infusion of insulin was given (Actrapid HM, 40 mIU/m 2 per min; Novo Nordisk, Copenhagen, Denmark) (19) . After achieving steady-state insulin levels of 100 µIU/mL within 10 minutes during the clamp (range, 80-125 µIU/mL), a variable infusion of 20% glucose was begun via a separate infusion pump, and the rate was Each subject was asked to avoid making any changes in her lifestyle or dietary habits during the study.
After three months, patients underwent a medical examination and a transvaginal ultrasonography only while a second hospitalization was performed six months later and the basal study was repeated.
OGTT blood samples were obtained basally and 30, 60, 90, 120, 180, and 240 minutes after the ingestion of 75 g of glucose. In all samples the glucose, insulin and C-peptide (C-pep) plasma levels were determined. For each interpretation, all samples from the same patient were assayed simultaneously. Samples for the measurement of basal and stimulated insulin and C-peptide, together with other hormones, were centrifuged promptly and the plasma stored at -20° C until required for assay.
All hormones were measured by commercial RIA kits (Radim, Rome, Italy). The intra-and interassay coefficients of variation were less than 8% and 15% for all hormones, respectively. Total cholesterol and triglyceride concentrations were determined by an enzymatic assay (Bristol, Paris, France). HDL concentrations were determined after precipitation of chylomicrons, VLDL, and LDL (Roche, Mannheim, Germany), and VLDL were separated (as the supernatant) from LDL and HDL by 8 lipoprotein ultracentrifugation. A magnesium chloride/phosphotungstic acid technique was used to precipitate LDL from the bottom fraction after ultracentrifugation. All lipid assays were performed according to our standard laboratory procedures.
Ultrasound assessment of endothelial-dependent and independent vasodilation of the brachial artery
The The vessel diameter was measured at the end of diastole, corresponding with the R wave on the ECG, at a fixed distance from an anatomical marker. In order to measure the FMD, the images were obtained at baseline and after 90 seconds from the deflation of a wrist cuff inflated to suprasystolic pressure (to at least 50 mmHg over the systolic blood pressure) for 5 minutes. The images to measure the nitrate mediated (endothelium-independent) dilatation (NMD) were acquired 4 minutes after the administration of sublingual glycerine trinitrate (0.3 mg). The FMD and NMD were calculated as the percentage increase in the arterial diameter during hyperemia compared with the diameter at rest.
Statistical Analysis
Data were stored and analyzed using SPSS software (statistical package for social science, release 6.0, SPSS, Inc., Chicago, IL) on an IBM-compatible computer. Distribution of the data was tested by the Kolmogorov-Smirnov test to verify whether the samples followed a normal distribution. The absolute differences between the two groups were compared using the Student's t test while the non parametric tests were applied to biochemical data that violated the assumption of normality. The estimated sample size for a two sided t-test with a 5% alpha error and with an 80% of power was equal to 12 subjects per group. A two-tailed P < 0.05 was considered statistically significant. All data are presented as mean ± SD.
RESULTS
Three patients from the placebo group A, dropped out because of the menopausal neurovegetative symptoms and two patients decided to withdraw. In the genistein treated group B , one patient withdrew due to another health problem and one patient was lost for unknown reason. Two more patients who completed the follow up, refused to undergo the hyperinsulinemic euglycemic clamps in the second hospitalization; therefore the data of the patients were removed from the table 2. Table 1 To better evaluate the effect of genistein administration on the glyco-insulinemic metabolism, we categorized the treated population into a hyperinsulinemic group (H),14 patients, and a normoinsulinemic group (N), 12 patients, revealing some differences between the two groups as shown in table 2. Table 2 illustrates the glycoinsulinemic metabolism and the lipid profile in these two subgroups. At baseline, BMI (P<0.05), fasting insulin and the AUC-I levels were significantly different between the two groups (both with P<0.005), as expected. Hyperinsulinemic group showed also basal C-Pep and stimulated AUC-pep values higher than normoinsulinemic patients as well as a higher HOMA-IR and HOMA-B index (P<0.005). The two groups didn't differ in basal total cholesterol, triglycerides and LDL-chol levels while HDL-chol levels were lower in hyperinsulinemic patients (P<0.005).
In the normoinsulinemic patients, a significant reduction in both fasting glucose and AUC-glucose plasma levels (P<0.05 and P<0.01 respectively) was observed after genistein treatment even if the delta values didn't differ significantly in comparison whit the hyperinsulinemic patients. No changes in the fasting insulin and C-pep levels were noticed and no relevant differences were found both in the insulin As concerns the lipid profile, the normoinsulinemic group didn't reveal any significant variation in the post-treatment assessment, while the hyperinsulinemic women showed a statistically significant increase in HDL cholesterol (P<0.05).
In the placebo group nine patients were normoinsulinemic and six patients were hyperinsulinemic, any statistical difference was observed after treatment (data not shown).
Endothelial function
In group A we observed a significant increase both in the FMD values (12.9±9 before therapy vs 22.8±18 after therapy, P<0.05) and in the NMD values (42.4±22 before therapy vs 143.5±90 after therapy, P<0.001) while we failed to find any significant variation both in FMD and in NMD in the placebo group. On the other hand substantial differences were found when comparing the normo and the hyperinsulinemic subgroups. After the 24-week therapy, the normoinsulinemic women showed an evident enhanced endothelial response to stimuli both in FMD and in NMD (P<0.02 and P<0.001 respectively) (Figure 1 ). In the hyperinsulinemic patients no significant differences in endothelial function were found after genistein treatment.
DISCUSSION
Recent studies have pointed out some beneficial effects of soy protein supplementation on several cardiovascular risk factors (24, 25) . Nevertheless during the last few years there have been many conflicting reports. Our data partially confirm the recent results on the glycemic metabolism and on vascular reactivity in postmenopausal women and show that the individual metabolic status influences the kind of response that genistein administration achieves.
In the present study, we found that the 6-month genistein treatment significantly improves the glycemic metabolism and endothelial function in postmenopausal women compared to the placebo group. Two previous studies showed either only modest estrogen-like effects of soy supplementation on insulin levels (26) or no effects on lipids or on insulin sensitivity in non-diabetic postmenopausal women who had taken 114mg/d of isolated isoflavones, respectively (27) . On the other hand, more recently,
Crisafulli et al. have reported that genistein administration for 6 months significantly lowers fasting insulin and glucose levels as well as improves HOMA-IR in healthy postmenopausal women (12) .
Furthermore, a following study showed the significantly positive effect of 54mg/d of genistein for 24 months on the glycemic and insulin metabolism when compared with the placebo group (16). Our results on treated patients are consistent with these findings and further support the beneficial effects of genistein on glycemic metabolism, although our population had a higher BMI.
In our study, we found different responses to the therapy in according to the patients' normoinsulinemic and hyperinsulinemic status. The glycoinsulinemic metabolism of our patients was studied in detail by analysing of the response to glucose load, and assessing the AUC-I as an index of hyperinsulinemia as well as by the evaluation of pancreatic insulin secretion (C-pep levels) and of hepatic insulin clearance (FHIE values). Therefore the indexes of insulin resistance were measured not only by the homeostasis model but also by the euglycemic hyperinsulinemic clamp technique, which is still considered as the gold standard for the determination of total body insulin action.
The subgroup of normoinsulinemic patients showed significant decrease in basal glucose levels as well as a reduction in AUC-glucose after genistein treatment . No change in the basal or stimulated insulin levels has been found in these patients, while the direct utilization of glucose by peripheral tissue (indicated by M index) tended to increase. The basal glucose levels reduction may be partially explained by an increased peripheral utilization but other mechanisms might also be involved. In fact, some studies have shown that isoflavones can inhibit the intestinal brush border uptake of glucose (28) According to previous observations (11)our work, while not observing any change in lipid markers in the whole population, indicated a significant increase of HDL in the hyperinsulinemic group and a trend toward a reduction in LDL-col levels.
Some recent studies have demonstrated that PHs may improve endothelial function (10, 25, 39, 40) .
Genistein acts through a receptor pathway having a high affinity with the beta estrogen receptor in the vessel wall, as well as a relative affinity to the alpha-estrogen receptor (41) . It has also been demonstrated that genistein shows antioxidant properties thorough the direct stimulation of endothelial 14 nitric oxide synthesis and the inhibition of the tyrosine kinase protein (41) while genistein induces an endothelium-independent relaxation without involving the endothelium or the eNOS pathway (42) .
As reported in previous randomized clinical trial, although genistein therapy improved the endotheliumdependent vasodilatation, it did not change the endothelial independent vasodilatation because of the limited number of patients tested (10) . The positive influence of isoflavones on endothelium-dependent vasodilatation was also demonstrated in healthy postmenopausal women by Colacurci et al. but no effect on the endothelium-independent mechanisms was observed even if a significant increase of basal brachial artery diameter after therapy was shown (24) .
In the present study, we have shown a significant improvement both in dependent and independent endothelium vasodilatation in normoinsulinemic patients. These findings agree both with the data demonstrating the improvement of FMD as well as with Hallund' s study concerning the endothelium independent vasodilatation (43) . Conversely patients with insulinemic imbalance lost the beneficial effects on the endothelium function . This may depend on the pre-existing endothelial dysfunction as it appears even in the early phases of type-2 diabetes (44).
In conclusion many discrepancies among studies on PHs may be due to differing effective doses and different types of isoflavones, as well as the variations in experimental conditions and in the model used. Moreover the bulk of recent works as well as our data seem to point out some beneficial effects on glycemic metabolism and on the vascular function. Our study has added the evidence that the preexistent metabolic status of any single patient may determine different effects in response to isoflavone therapy. 
